High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients
Introduction and objectivesCheckpoint inhibition has emerged as new therapeutic option in muscle-invasive bladder cancer. The objective of the present study was to evaluate the prognostic role of PD1 and PDL1 expression in non-muscle-invasive bladder cancer (NMIBC) and establish an objective measuri...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Cancer immunology immunotherapy
Year: 2017, Jahrgang: 67, Heft: 3, Pages: 403-412 |
| ISSN: | 1432-0851 |
| DOI: | 10.1007/s00262-017-2093-9 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00262-017-2093-9 Verlag, Volltext: https://link.springer.com/article/10.1007/s00262-017-2093-9 
|
| Verfasserangaben: | Johannes Breyer, Ralph M. Wirtz, Wolfgang Otto, Philipp Erben, Thomas S. Worst, Robert Stoehr, Markus Eckstein, Stefan Denzinger, Maximilian Burger, Arndt Hartmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1577451198 | ||
| 003 | DE-627 | ||
| 005 | 20220814190152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180710r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00262-017-2093-9 |2 doi | |
| 035 | |a (DE-627)1577451198 | ||
| 035 | |a (DE-576)507451198 | ||
| 035 | |a (DE-599)BSZ507451198 | ||
| 035 | |a (OCoLC)1341013570 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Breyer, Johannes |e VerfasserIn |0 (DE-588)1155510593 |0 (DE-627)1017777454 |0 (DE-576)501694145 |4 aut | |
| 245 | 1 | 0 | |a High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients |c Johannes Breyer, Ralph M. Wirtz, Wolfgang Otto, Philipp Erben, Thomas S. Worst, Robert Stoehr, Markus Eckstein, Stefan Denzinger, Maximilian Burger, Arndt Hartmann |
| 264 | 1 | |c 2018 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 17 November 2017 | ||
| 500 | |a Gesehen am 10.07.2018 | ||
| 520 | |a Introduction and objectivesCheckpoint inhibition has emerged as new therapeutic option in muscle-invasive bladder cancer. The objective of the present study was to evaluate the prognostic role of PD1 and PDL1 expression in non-muscle-invasive bladder cancer (NMIBC) and establish an objective measuring method using RNA quantification.Materials and methodsWe retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder. mRNA expression of PD1, PDL1 and CD3 was measured by single step RT-qPCR and correlated to clinicopathological parameters, recurrence-free survival (RFS), progression-free survival (PFS) and carcinoma-specific survival (CSS).ResultsWe have analyzed 334 patients with NMIBC at stage pT1 for mRNA analysis. Data from 296 patients (79% male, median age: 72 years) could be used. Spearman correlation revealed significant associations between mRNA expressions of PD1/PDL1 (ρ: 0.6024, p < 0.0001), CD3/PDL1 (ρ: 0.5728, p < 0.0001) and CD3/PD1 (ρ: 0.7005, p < 0.0001). Kaplan-Meier analysis revealed that high PDL1 mRNA expression (≥ 33.83) is a favorable prognostic factor with regard to better RFS (p = 0.0018), PFS (p = 0.021) and CSS (p = 0.012). Multivariate Cox-regression analysis proved PDL1 expression to be an independent prognosticator for RFS [HR 0.48 (0.31-0.72), p = 0.0005], PFS [HR 0.45 (0.24-0.80), p = 0.0059] and CSS [HR 0.31 (0.13-0.67), p = 0.0021].ConclusionHigh mRNA expression of PDL1 predicts improved RFS, PFS and CSS of pT1 NMIBC. Following prospective validation, this objective measurement of PD-L1 might help stratify patients with NMIBC for immunotherapy and identify patients who might benefit from early cystectomy. | ||
| 534 | |c 2017 | ||
| 700 | 1 | |a Erben, Philipp |d 1973- |e VerfasserIn |0 (DE-588)128501014 |0 (DE-627)373920997 |0 (DE-576)297181661 |4 aut | |
| 700 | 1 | |a Worst, Thomas |d 1985- |e VerfasserIn |0 (DE-588)1028335679 |0 (DE-627)73058500X |0 (DE-576)375827501 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology immunotherapy |d Berlin : Springer, 1976 |g 67(2018), 3, Seite 403-412 |h Online-Ressource |w (DE-627)253390443 |w (DE-600)1458489-X |w (DE-576)072283475 |x 1432-0851 |7 nnas |a High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients |
| 773 | 1 | 8 | |g volume:67 |g year:2018 |g number:3 |g pages:403-412 |g extent:10 |a High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00262-017-2093-9 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s00262-017-2093-9 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180710 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1028335679 |a Worst, Thomas |m 1028335679:Worst, Thomas |d 60000 |d 63100 |e 60000PW1028335679 |e 63100PW1028335679 |k 0/60000/ |k 1/60000/63100/ |p 5 | ||
| 998 | |g 128501014 |a Erben, Philipp |m 128501014:Erben, Philipp |d 60000 |d 63100 |e 60000PE128501014 |e 63100PE128501014 |k 0/60000/ |k 1/60000/63100/ |p 4 | ||
| 999 | |a KXP-PPN1577451198 |e 3017204138 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title":"High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients","title_sort":"High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients"}],"name":{"displayForm":["Johannes Breyer, Ralph M. Wirtz, Wolfgang Otto, Philipp Erben, Thomas S. Worst, Robert Stoehr, Markus Eckstein, Stefan Denzinger, Maximilian Burger, Arndt Hartmann"]},"person":[{"family":"Breyer","given":"Johannes","role":"aut","display":"Breyer, Johannes"},{"display":"Erben, Philipp","given":"Philipp","role":"aut","family":"Erben"},{"display":"Worst, Thomas","role":"aut","given":"Thomas","family":"Worst"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"recId":"1577451198","note":["Published online: 17 November 2017","Gesehen am 10.07.2018"],"relHost":[{"note":["Gesehen am 15.05.2024","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 52.2003: Supplement"],"id":{"issn":["1432-0851"],"zdb":["1458489-X"],"eki":["253390443"]},"disp":"High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patientsCancer immunology immunotherapy","physDesc":[{"extent":"Online-Ressource"}],"recId":"253390443","origin":[{"dateIssuedDisp":"1976-","publisher":"Springer","dateIssuedKey":"1976","publisherPlace":"Berlin ; Heidelberg"}],"titleAlt":[{"title":"CII"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"year":"2018","text":"67(2018), 3, Seite 403-412","volume":"67","pages":"403-412","extent":"10","issue":"3"},"language":["eng"],"title":[{"title":"Cancer immunology immunotherapy","subtitle":"CII","title_sort":"Cancer immunology immunotherapy"}],"pubHistory":["1.1976 -"]}],"physDesc":[{"extent":"10 S."}],"id":{"doi":["10.1007/s00262-017-2093-9"],"eki":["1577451198"]}} | ||
| SRT | |a BREYERJOHAHIGHPDL1MR2018 | ||